Procaps Group

About Us

Procaps Group, S.A. ("Procaps Group") (NASDAQ: PROC) is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,300 collaborators working under a sustainable model. Procaps develops, manufactures, and markets over the counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.

ESG Report 2021

Committed to Innovation for a Healthier World

Read more
ESG Report

Press Realease

Procaps Group Reports First Quarter 2023 Results

Constant Currency Net Revenues Increased 10% Quarter-over-Quarter in 1Q23, and 22% increase in Adjusted EBITDA, With Strong Demand of RX and Softgel Portfolios, Offset by Clinical Specialty Covid Portfolio MIAMI and BARRANQUILLA, Colombia, June 05, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A.

June 5, 2023 

Read more

Pharmaceutical Group
dedicated to delivering
health and nutrition

We employ over 5,300 people across 13 countries

Our products reach 
50+ markets

Virtual Tour